Iterum Therapeutics PLC (ITRM)

0.492 +0.004 (+0.84%)
Real-time Cboe USD Disclaimer

Iterum Therapeutics PLC Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
7
Equity Type
ORD
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Contact Information
Address
Harcourt Street Dublin,2 Ireland
Phone
353 1 903 8920
Fax
-
Top Executives
Name
Age
Since
Title
Michael W. Dunne 61 2015 Strategic Advisor & Director
Brenton K. Ahrens 58 2015 Independent Interim Chairman
Corey N. Fishman 56 2015 President, CEO & Director
Mark Chin 39 2017 Independent Director
David George Kelly 60 2016 Independent Director
Beth P. Hecht 57 2021 Independent Director
Ronald M. Hunt 56 2015 Independent Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.